Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCD1 | P51178 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | FGF1 | P05230 | 1/20 | 0.41 |
| ▸ | FGF2 | P09038 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.41 |
| ▸ | HLCS | P50747 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926090 | 0.99 | PLCD1 (0.48) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL5685965 | 0.96 | F2 (0.47) | PLCD1F2HLCS | |
| SCHEMBL7532610 | 0.92 | PLCD1 (0.48) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL7644975 | 0.92 | PLCD1 (0.43) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL20129499 | 0.88 | PLCD1 (0.49) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL29426309 | 0.87 | PLCD1 (0.49) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL9004512 | 0.87 | F2 (0.43) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL29627228 | 0.86 | PLCD1 (0.47) | PLCD1F2FGF1FGF2VEGFA | |
| Biotin SCHEMBL9489122 | 0.86 | F2 (0.48) | F2HLCSTDP1 | |
| SCHEMBL6534840 | 0.84 | TK1 (0.46) | F2FGF1FGF2VEGFAHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054337-A1 | CO-TARGETING NCOA3 AND PD-1 FOR CANCER THERAPY | SUTTER BAY HOSPITALS (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025039033-A1 | METHODS AND REAGENTS FOR DIAGNOSIS AND/OR PROGNOSIS OF TRAUMATIC BRAIN INJURY | GLIA DIAGNOSTICS PTY LTD (AU) | 2025-02-27 | — | — | WO | disclosed |
| EP-3274008-B1 | DETECTION OF BRAIN INJURY | THE UNIV OF MONTANA (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20220290159-A1 | miRNAS FOR REDUCING VENTRICLE ENLARGEMENT | St. Jude Children's Research Hpspital, Inc. (US) | 2022-09-15 | — | — | US | disclosed |
| CN-107427614-B | Detection of brain injury | 蒙大拿大学 | 2021-10-15 | — | — | CN | disclosed |
| US-11142796-B2 | MIR-18B for use as a marker of cancer progression and target for therapies to treat cancer | SUTTER BAY HOSPITALS (US) | 2021-10-12 | — | — | US | disclosed |
| EP-2898098-B1 | MIR-18B FOR USE AS A MARKER OF CANCER PROGRESSION AND TARGET FOR THERAPIES TO TREAT CANCER | SUTTER WEST BAY HOSPITALS (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2021016425-A1 | MIRNAS FOR REDUCING VENTRICLE ENLARGEMENT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-10815529-B2 | Detection of traumatic brain injury | THE UNIVERSITY OF MONTANA (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190352716-A1 | DETECTION OF TRAUMATIC BRAIN INJURY | THE UNIVERSITY OF MONTANA (US) | 2019-11-21 | — | — | US | disclosed |
| US-20020177138-A1 | Methods for the indentification of textual and physical structured query fragments for the analysis of textual and biopolymer information | THE UNITED STATES OF AMERICA , REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-11-28 | — | — | US | disclosed |
| EP-1066411-A1 | METHODS FOR CANCER PROGNOSIS AND SCREENING ANTIPROLIFERATIVE AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999050455-A1 | METHODS FOR CANCER PROGNOSIS AND SCREENING ANTIPROLIFERATIVE AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999039200-A1 | MOLECULAR MARKERS FOR DIAGNOSING HEPATOCELLULAR CARCINOMA | THOMAS JEFFERSON UNIVERSITY (US) | 1999-08-05 | — | — | WO | disclosed |
| EP-0906448-A1 | METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER | THOMAS JEFFERSON UNIVERSITY (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5840506-A | QUANTIFYING THE EXPRESSION OF TUMOR SUPPRESSOR GENE PRB2/P130 BY MEASURING MESSENGER RNA OR PROTEIN; IMMUNOHISTOCHEMICAL STAINING OF TISSUE BIOPSIES | THOMAS JEFFERSON UNIVERSITY (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1997038125-A1 | METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER | THOMAS JEFFERSON UNIVERSITY (US) | 1997-10-16 | — | — | WO | disclosed |
| US-5427916-A | Measuring gene expression(through determinations of genetic transcription) of growth-controlling oncogenes, then comparing values obtained before and after administering antitumor agents | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0341904-B1 | Method for predicting the effectiveness of antineoplastic therapy in individual patients | UNIV TEMPLE (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0341904-A2 | Method for predicting the effectiveness of antineoplastic therapy in individual patients | Temple University of the Commonwealth System of Higher Education (US) | 1989-11-15 | — | — | EP | disclosed |